Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

The i-port®

Davida Kruger and KK Patton

The i-port®

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

View all Videos…
Victoza Archives
Browse the Victoza Archives
Subscribe to the Medications RSS Feed

Victoza

Medications RSS Feed RSS
Page 2
« Previous Page
FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.
news
FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.

Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.

Comments 0 comments - Feb 27, 2010 - * * * * *

Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza
news
Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza

Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.

Comments 0 comments - Feb 1, 2010 - * * * * *

Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes
news
Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Comments 0 comments - Jan 28, 2010 - * * * * *

Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”
news
Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

Comments 0 comments - May 6, 2009 - * * * * *

« Previous Page
©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.